Successful treatment of refractory livedoid vasculopathy in a patient with systemic lupus erythematosus
Keywords:Livedoid vasculopathy, SLE, Treatment
Livedoid vasculopathy (LV) also known as livedoid vasculitis is a rare and chronic thrombotic vasculopathy that typically affects the lower extremities. Diagnosis of LV are not well defined and the treatment are widely varied. We report a case of 30 years old female patient diagnosed with Livedoid vasculopathy and systemic lupus erythematous as underlying diseases. Patient presented with chief complain painful ulcer on her bilateral lower extremities. Hypercoagulable state was normal. Skin biopsy found that dermal vessels filled with erythrocytes extravasation and inflammation cell PMN. ANA profile was positive for RNP/Sm suggest that a systemic lupus erythematosus. Patient underwent successful treatment planning for methylprednisolone 16 mg twice daily, hydroxychloroquine 200 mg once daily and methotrexate 10 mg once a week. The ulcer completely resolved after 2 months of the treatment and had no recurrent ulcer. LV is a rare, chronic, and occlusive disease of the veins supplying the upper parts of the skin. Histopathological finding is thickening or hyaline changes in the walls of superficial dermal vessels and luminal fibrin deposition. Red cell extravasation and perivascular lymphocytic infiltrates are expected findings. SLE was underlying condition that cause endothelial injury and leads to thrombosis of the dermal vessels. no treatment guidelines are available for LV. Methylprednisolone, hydroxychloroquine and methotrexate have successful therapeutic response to a patient with ulcerative LV and SLE as underlying diseases.
Asli Bilgic, Salih 1. Khenifer S, Thomas L, Balme B, Dalle S. Livedoid vasculopathy: thrombotic or inflammatory disease. Clin Exp Dermatol. 2010;35:693-8.
Kerk N, Goerge T. Livedoid vasculopathy - a thrombotic disease. Vasa. 2013;42(5):317-22.
Criado PR, Rivitti EA, Sotto MN, Valente NYS, Aoki V, de Carvalho JF, et al. Livedoid vasculopathy: an intringuing cutaneous disease. An Bras Dermatol. 2011;86(5):961-77.
Micieli R, Alavi A. Treatment for Livedoid Vasculopathy: A Systematic Review. JAMA Dermatol. 2018;154(2):193-202.
Bilgic A, Ozcobanoglu S, Bozca BC, Alpsoy E. Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management. Int J Women's Dermatol. 2021;7(5 Part A):588-99.
Vaseduvan B, Neema S, Verma R. Livedoid vasculopathy: A review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol. 2016;82:478-88
Soter NA, cutaneous necrotizing venulitis in Kang S, Amagai M, Bruckner AL, Alexander H, Margolis D, et al (eds). Fitzpatrick’s Dermatology 9th ed. New York, McGraw-Hill; 2019(2): 2527-2538.
Levell NJ, Mukhtyar C, cutaneous vasculitis in Christopher E, barker J, Bleiker T, Chalmers R, et al. Rooks textbook of Dermatology 9th edition. West Sussex, Willey Blackwell; 2016(4): 102.1
Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an Old Drug with New Tricks. Int J Mol Sci. 2019;20(20):5023.
Freitas TQ, Halpern I, Criado PR. Livedoid vasculopathy: a compelling diagnosis. Autops Case Rep. 2018;8(3):34.